Analgesic efficacy of naproxen-codeine, naproxen+dexamethasone, and naproxen on myofascial pain: A randomized double-blind controlled trial

Cranio. 2023 Mar;41(2):119-125. doi: 10.1080/08869634.2020.1824411. Epub 2020 Sep 17.

Abstract

Objective: To assess the effects of naproxen sodium-codeine phosphate, naproxen sodium-dexamethasone, and naproxen sodium on myofascial pain.

Methods: This randomized, double-blind prospective clinical study was conducted with patients who applied with the complaint of pain in the temporomandibular region. A total of 169 patients were randomly divided into four groups and received the following treatments: Group A: naproxen sodium 550 mg; Group B: naproxen sodium 550 mg + codeine phosphate 30 mg; Group C: naproxen sodium 550 mg + single-dose dexamethasone 8 mg, and Group D: paracetamol 500 mg.

Results: Of the patients, 132 were female, and 37 were male, with a mean age of 27.04 ± 10.56 (18-69 years). Analgesic efficiency of the naproxen sodium-codeine phosphate group was the most effective at the 2nd week and 4th week (p < 0.05).

Conclusion: Naproxen sodium-codeine phosphate might be preferred as an analgesic in similar cases with severe myofascial pain.

Keywords: Temporomandibular disorders; codeine; dexamethasone; naproxen; pain.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Analgesics
  • Codeine* / therapeutic use
  • Dexamethasone
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Naproxen* / therapeutic use
  • Postoperative Pain
  • Prospective Studies
  • Young Adult

Substances

  • Naproxen
  • Codeine
  • Analgesics
  • Dexamethasone